Published in Arthritis Rheum on July 01, 1998
Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis (1999) 1.97
Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. Ann Rheum Dis (2001) 1.33
Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol (2012) 1.18
Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis (2010) 1.01
Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy. Clin Rheumatol (2014) 0.89
The rate of polymyalgia rheumatica (PMR) and remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in a clinic where primary care physicians are working in Japan. Rheumatol Int (2011) 0.82
Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica. Ther Adv Musculoskelet Dis (2014) 0.79
Induction of remission is difficult due to frequent relapse during tapering steroids in Korean patients with polymyalgia rheumatica. J Korean Med Sci (2011) 0.78
Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int (2012) 0.78
Gait characteristics associated with the foot and ankle in inflammatory arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord (2015) 0.75
Can HLA-DR explain the varying frequency of synovitis in polymyalgia rheumatica? Comment on the article by Salvarani et al. Arthritis Rheum (1999) 0.75
Magnetic resonance imaging in the differential diagnosis between polymyalgia rheumatica and elderly onset rheumatoid arthritis. Clin Rheumatol (2005) 0.75
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum (1991) 11.66
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
EULAR recommendations for the management of Behçet disease. Ann Rheum Dis (2008) 3.37
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Retrocalcaneal bursitis in spondyloarthropathy: assessment by ultrasonography and magnetic resonance imaging. J Rheumatol (1998) 2.68
Coexistence of ochronosis and ankylosing spondylitis. J Rheumatol (1990) 2.30
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum (1995) 2.16
Epidemiologic and clinical aspects of Behçet's disease in a defined area of Northwestern Spain, 1988-1997. J Rheumatol (2000) 2.12
Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis (1999) 1.97
Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum (1991) 1.80
Psoriatic arthritis. Curr Opin Rheumatol (1998) 1.69
Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) (2008) 1.69
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum (2001) 1.68
Genetic markers and quantitative genetic variation in Medicago truncatula (Leguminosae): a comparative analysis of population structure. Genetics (1996) 1.65
Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis (2008) 1.65
Divergent evolution of dispersal in a heterogeneous landscape. Evolution (2001) 1.63
Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Pediatr Hematol Oncol (1997) 1.54
Lymphocyte subpopulations analysis in peripheral blood in polymyalgia rheumatica/giant cell arteritis. Br J Rheumatol (1993) 1.52
Comparative allozyme and microsatellite population structure in a narrow endemic plant species, Centaurea corymbosa Pourret (Asteraceae). Mol Ecol (2001) 1.51
Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol (2000) 1.48
Dactylitis also involving the synovial sheaths in the palm of the hand: two more cases studied by magnetic resonance imaging. Ann Rheum Dis (1998) 1.44
Polymyalgia rheumatica: a disorder of extraarticular synovial structures? J Rheumatol (1999) 1.44
One-year outcome in multivessel coronary disease patients undergoing coronary stenting. Catheter Cardiovasc Interv (1999) 1.38
Low incidence of proteinuria in RA after gold thiosulfate treatment. J Rheumatol (1990) 1.38
[Histopathologic features in atherectomy samples obtained from patient with unstable angina, stable angina and restenosis. Directional Atherectomy Lombardi Group]. G Ital Cardiol (1996) 1.38
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation (1998) 1.37
Centaurea corymbosa, a cliff-dwelling species tottering on the brink of extinction: a demographic and genetic study. Proc Natl Acad Sci U S A (1997) 1.35
Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis (2008) 1.32
RS3PE syndrome: an overview. Clin Exp Rheumatol (2000) 1.32
The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol (2000) 1.30
Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum (2001) 1.27
Inbreeding depression in small populations of self-incompatible plants. Genetics (2001) 1.27
Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol (2001) 1.24
Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. Clin Exp Rheumatol (2000) 1.24
Behçet's disease and cardiovascular involvement. Lupus (2005) 1.23
Characterization of the binding interface between the copper chaperone Atx1 and the first cytosolic domain of Ccc2 ATPase. J Biol Chem (2001) 1.22
Genetic diversity and population structure of an insular tree, Santalum austrocaledonicum in New Caledonian archipelago. Mol Ecol (2005) 1.20
Evolution of reproductive effort in a metapopulation with local extinctions and ecological succession. Am Nat (1997) 1.19
Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol (2005) 1.16
Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum (2000) 1.15
Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) (2008) 1.13
Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis (2002) 1.13
Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. Rheumatol Int (2000) 1.13
Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis (2006) 1.12
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) (2008) 1.12
Late onset undifferentiated seronegative spondyloarthropathy. J Rheumatol (1995) 1.11
Classification of inflammatory arthritis. Lancet (1998) 1.07
Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med (1997) 1.07
Vascular endothelial growth factor production in polymyalgia rheumatica. Arthritis Rheum (2000) 1.06
Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford) (2007) 1.06
Fine-scale genetic structure and gene dispersal in Centaurea corymbosa (Asteraceae) I. Pattern of pollen dispersal. J Evol Biol (2004) 1.05
Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol (1995) 1.05
Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol (2001) 1.04
Permanent Genetic Resources added to Molecular Ecology Resources database 1 January 2009-30 April 2009. Mol Ecol Resour (2009) 1.04
HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol (2008) 1.03
Adaptation in a spider mite population after long-term evolution on a single host plant. J Evol Biol (2007) 1.03
Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases? J Rheumatol (1997) 1.02